123 related articles for article (PubMed ID: 36629283)
21. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
Matsuo K; Hasegawa K; Yoshino K; Murakami R; Hisamatsu T; Stone RL; Previs RA; Hansen JM; Ikeda Y; Miyara A; Hiramatsu K; Enomoto T; Fujiwara K; Matsumura N; Konishi I; Roman LD; Gabra H; Fotopoulou C; Sood AK
Eur J Cancer; 2015 Sep; 51(14):1978-88. PubMed ID: 26238017
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin.
Sirichaisutdhikorn D; Suprasert P; Khunamornpong S
Asian Pac J Cancer Prev; 2009; 10(6):1041-5. PubMed ID: 20192580
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.
Zhu C; Zhu J; Qian L; Liu H; Shen Z; Wu D; Zhao W; Xiao W; Zhou Y
BMC Cancer; 2021 Mar; 21(1):322. PubMed ID: 33766002
[TBL] [Abstract][Full Text] [Related]
24. Endometriosis-associated ovarian cancer is not a distinct clinical entity among young patients: A 12-year cohort study.
Cai Y; Yin J; Jin Y; Li Y; Wu M; Yang J; Huang H; Leng J; Pan L
Eur J Surg Oncol; 2020 May; 46(5):876-882. PubMed ID: 31837932
[TBL] [Abstract][Full Text] [Related]
25. Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histology-A Comparative Study.
Schnack TH; Høgdall E; Nedergaard L; Høgdall C
Int J Gynecol Cancer; 2016 Jan; 26(1):82-90. PubMed ID: 26569060
[TBL] [Abstract][Full Text] [Related]
26. Friend or foe? The prognostic role of endometriosis in women with clear cell ovarian carcinoma. A UK population-based cohort study.
Tranoulis A; Buruiana FH; Gupta B; Kwong A; Lakhiani A; Yap J; Balega J; Singh K
Arch Gynecol Obstet; 2022 May; 305(5):1279-1289. PubMed ID: 34468823
[TBL] [Abstract][Full Text] [Related]
27. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.
Chen X; Zhang J; Cheng W; Chang DY; Huang J; Wang X; Jia L; Rosen DG; Zhang W; Yang D; Gershenson DM; Sood AK; Bast RC; Liu J
Int J Gynecol Cancer; 2013 Jun; 23(5):815-22. PubMed ID: 23669443
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
Gallego A; Ramon-Patino J; Brenes J; Mendiola M; Berjon A; Casado G; Castelo B; Espinosa E; Hernandez A; Hardisson D; Feliu J; Redondo A
Clin Transl Oncol; 2021 Mar; 23(3):536-542. PubMed ID: 32651885
[TBL] [Abstract][Full Text] [Related]
29. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
30. Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer.
Schnack TH; Oliveira DNP; Christiansen AP; Høgdall C; Høgdall E
Cancer Genet; 2023 Nov; 278-279():9-16. PubMed ID: 37567101
[TBL] [Abstract][Full Text] [Related]
31. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes.
Nasioudis D; Mastroyannis SA; Albright BB; Haggerty AF; Ko EM; Latif NA
Gynecol Oncol; 2018 Jul; 150(1):14-18. PubMed ID: 29751993
[TBL] [Abstract][Full Text] [Related]
33. The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma.
Hogen L; Thomas G; Bernardini M; Bassiouny D; Brar H; Gien LT; Rosen B; Le L; Vicus D
Gynecol Oncol; 2016 Nov; 143(2):258-263. PubMed ID: 27623251
[TBL] [Abstract][Full Text] [Related]
34. Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.
Ceppi L; Grassi T; Galli F; Buda A; Aletti G; Lissoni AA; Adorni M; Garbi A; Colombo N; Bonazzi C; Landoni F; Fruscio R
Gynecol Oncol; 2021 Jan; 160(1):64-70. PubMed ID: 33077259
[TBL] [Abstract][Full Text] [Related]
35. Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy?
Gadducci A; Notarnicola M; Menichetti A; Lanfredini N; Fanucchi A; Cosio S
Eur J Gynaecol Oncol; 2016; 37(2):182-8. PubMed ID: 27172742
[TBL] [Abstract][Full Text] [Related]
36. Clinical and pathologic features of patients with rare ovarian tumors: multi-center review of 167 patients by the anatolian society of medical oncology.
Bilici A; Inanc M; Ulas A; Akman T; Seker M; Babacan NA; Inal A; Bal O; Koral L; Sevinc A; Tufan G; Elkiran ET; Ustaalioglu BB; Yavuzsen T; Alkis N; Ozkan M; Gumus M
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6493-9. PubMed ID: 24377556
[TBL] [Abstract][Full Text] [Related]
37. The impact of lymphadenectomy on the survival outcomes of ovarian clear cell carcinoma: A retrospective study of the SEER database and Chinese registry.
Liu Y; Zhao W; Huang C; Chu R; Li Z; Wang Y; Song L; Li L
Eur J Surg Oncol; 2024 Mar; 50(3):107975. PubMed ID: 38295548
[TBL] [Abstract][Full Text] [Related]
38. Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion.
Matsuo K; Yoshino K; Hasegawa K; Murakami R; Ikeda Y; Adachi S; Hiramatsu K; Yokoyama T; Nishimura M; Sheridan TB; Enomoto T; Fujiwara K; Matsumura N; Konishi I; Fotopoulou C; Roman LD; Sood AK
Gynecol Oncol; 2015 Feb; 136(2):198-204. PubMed ID: 25497604
[TBL] [Abstract][Full Text] [Related]
39. Lymphocyte-activation gene 3 protein expression in tumor-infiltrating lymphocytes is associated with a poor prognosis of ovarian clear cell carcinoma.
Zaitsu S; Yano M; Adachi S; Miwa M; Katoh T; Kawano Y; Yasuda M
J Ovarian Res; 2023 May; 16(1):93. PubMed ID: 37179337
[TBL] [Abstract][Full Text] [Related]
40. Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?
Kajiyama H; Mizuno M; Shibata K; Umezu T; Suzuki S; Yamamoto E; Mitsui H; Sekiya R; Niimi K; Kawai M; Nagasaka T; Kikkawa F
Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():305-10. PubMed ID: 25203309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
